DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,044 filers reported holding DANAHER CORPORATION in Q1 2016. The put-call ratio across all filers is 0.83 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $154,544 | -3.9% | 618,547 | -3.9% | 0.33% | -2.7% |
Q1 2024 | $160,737 | +4.4% | 643,670 | -3.2% | 0.34% | -2.6% |
Q4 2023 | $153,892 | -9.7% | 665,218 | -3.1% | 0.34% | -16.3% |
Q3 2023 | $170,375 | -1.3% | 686,720 | -4.5% | 0.41% | +5.9% |
Q2 2023 | $172,562 | -8.0% | 719,007 | -3.4% | 0.39% | -11.8% |
Q1 2023 | $187,521 | -5.5% | 744,011 | -0.5% | 0.44% | -9.8% |
Q4 2022 | $198,531 | -99.9% | 747,989 | +0.1% | 0.49% | -2.8% |
Q3 2022 | $192,922,000 | +2.2% | 746,920 | +0.3% | 0.50% | +8.4% |
Q2 2022 | $188,832,000 | -13.7% | 744,842 | -0.2% | 0.46% | +3.6% |
Q1 2022 | $218,818,000 | -10.8% | 745,979 | +0.1% | 0.45% | -5.9% |
Q4 2021 | $245,236,000 | +7.9% | 745,375 | -0.2% | 0.48% | -1.0% |
Q3 2021 | $227,298,000 | +10.7% | 746,611 | -2.4% | 0.48% | +11.9% |
Q2 2021 | $205,252,000 | +13.3% | 764,840 | -5.0% | 0.43% | +10.0% |
Q1 2021 | $181,132,000 | -4.2% | 804,744 | -5.5% | 0.39% | -5.6% |
Q4 2020 | $189,097,000 | +0.7% | 851,251 | -2.4% | 0.41% | -9.2% |
Q3 2020 | $187,831,000 | +15.1% | 872,296 | -5.5% | 0.46% | +11.0% |
Q2 2020 | $163,206,000 | +26.8% | 922,953 | -0.7% | 0.41% | +5.4% |
Q1 2020 | $128,677,000 | -12.4% | 929,677 | -2.8% | 0.39% | +14.1% |
Q4 2019 | $146,815,000 | +8.8% | 956,577 | +2.4% | 0.34% | 0.0% |
Q3 2019 | $134,883,000 | +0.5% | 933,900 | -0.6% | 0.34% | +0.3% |
Q2 2019 | $134,235,000 | +8.5% | 939,233 | +0.2% | 0.34% | +8.3% |
Q1 2019 | $123,763,000 | +28.3% | 937,454 | +0.2% | 0.31% | +15.0% |
Q4 2018 | $96,478,000 | -7.9% | 935,590 | -2.9% | 0.27% | +11.4% |
Q3 2018 | $104,708,000 | +8.1% | 963,627 | -1.9% | 0.24% | +3.8% |
Q2 2018 | $96,891,000 | -1.7% | 981,874 | -2.4% | 0.24% | -1.7% |
Q1 2018 | $98,532,000 | +3.7% | 1,006,354 | -1.7% | 0.24% | +6.7% |
Q4 2017 | $95,027,000 | +7.9% | 1,023,774 | -0.3% | 0.22% | +2.3% |
Q3 2017 | $88,108,000 | -0.6% | 1,027,144 | -2.3% | 0.22% | -2.7% |
Q2 2017 | $88,682,000 | -2.6% | 1,050,863 | -1.3% | 0.23% | -2.6% |
Q1 2017 | $91,025,000 | +7.5% | 1,064,243 | -2.2% | 0.23% | +5.0% |
Q4 2016 | $84,705,000 | -2.6% | 1,088,190 | -1.9% | 0.22% | -4.3% |
Q3 2016 | $86,959,000 | -23.5% | 1,109,308 | -1.5% | 0.23% | -22.7% |
Q2 2016 | $113,728,000 | +6.6% | 1,126,018 | +0.1% | 0.30% | +6.0% |
Q1 2016 | $106,733,000 | +7.9% | 1,125,159 | +5.6% | 0.28% | +7.2% |
Q4 2015 | $98,938,000 | +8.4% | 1,065,224 | -0.6% | 0.26% | +2.7% |
Q3 2015 | $91,305,000 | -4.0% | 1,071,531 | -3.6% | 0.26% | +3.6% |
Q2 2015 | $95,140,000 | -0.5% | 1,111,581 | -1.3% | 0.25% | +1.6% |
Q1 2015 | $95,650,000 | -50.7% | 1,126,614 | -50.2% | 0.24% | -0.8% |
Q4 2014 | $193,886,000 | +125.4% | 2,262,122 | +99.8% | 0.24% | +8.9% |
Q3 2014 | $86,024,000 | -4.2% | 1,132,197 | -0.7% | 0.22% | -3.4% |
Q2 2014 | $89,787,000 | +2.2% | 1,140,445 | -2.7% | 0.23% | +0.9% |
Q1 2014 | $87,886,000 | -4.0% | 1,171,816 | -1.2% | 0.23% | -2.9% |
Q4 2013 | $91,576,000 | +9.6% | 1,186,222 | -1.6% | 0.24% | +3.5% |
Q3 2013 | $83,535,000 | +6.8% | 1,205,068 | -2.5% | 0.23% | +4.5% |
Q2 2013 | $78,243,000 | – | 1,236,073 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |